|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
decreases expression |
ISO |
belinostat results in decreased expression of ABCC6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
decreases expression |
ISO |
belinostat results in decreased expression of ABL1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
decreases expression |
ISO |
belinostat results in decreased expression of ACACB mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
increases expression |
ISO |
belinostat results in increased expression of ACADSB mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
ISO |
belinostat results in increased expression of ACKR3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
decreases expression |
ISO |
belinostat results in decreased expression of ACP5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
decreases expression |
ISO |
belinostat results in decreased expression of ACSL5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Ada |
adenosine deaminase |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of ADA mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of ADAM12 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adamts15 |
ADAM metallopeptidase with thrombospondin type 1 motif, 15 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249
|
|
G |
Adamts3 |
ADAM metallopeptidase with thrombospondin type 1, motif 3 |
decreases expression |
ISO |
belinostat results in decreased expression of ADAMTS3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:18,231,128...18,437,771
Ensembl chr14:18,231,165...18,435,556
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ADCYAP1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA belinostat results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adgrl3 |
adhesion G protein-coupled receptor L3 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of ADGRL3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860
|
|
G |
Adi1 |
acireductone dioxygenase 1 |
decreases expression |
ISO |
belinostat results in decreased expression of ADI1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842
|
|
G |
Afp |
alpha-fetoprotein |
decreases expression |
ISO |
belinostat results in decreased expression of AFP mRNA |
CTD |
PMID:26272509 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ak7 |
adenylate kinase 7 |
increases expression |
ISO |
belinostat results in increased expression of AK7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:124,611,789...124,679,978
Ensembl chr 6:124,611,902...124,679,961
|
|
G |
Akna |
AT-hook transcription factor |
decreases expression |
ISO |
belinostat results in decreased expression of AKNA mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
belinostat results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23671600 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
decreases expression |
ISO |
belinostat results in decreased expression of ALDOB mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
decreases expression |
ISO |
belinostat results in decreased expression of AMPD3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ANGPT1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
decreases expression |
ISO |
belinostat results in decreased expression of ANGPT2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Ano3 |
anoctamin 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ANO3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anxa2 |
annexin A2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ANXA2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
belinostat results in decreased expression of ANXA4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression |
ISO |
belinostat results in decreased expression of AOX1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap5m1 |
adaptor related protein complex 5 subunit mu 1 |
increases expression |
ISO |
belinostat results in increased expression of AP5M1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:22,355,478...22,385,222
Ensembl chr15:22,355,500...22,377,750
|
|
G |
Apela |
apelin receptor early endogenous ligand |
increases expression |
ISO |
belinostat results in increased expression of APELA mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:24,694,356...24,703,466
Ensembl chr16:24,694,324...24,703,465
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
ISO |
belinostat results in decreased expression of APOC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
decreases expression |
ISO |
belinostat results in decreased expression of ARAP3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:29,806,214...29,834,217
Ensembl chr18:29,807,536...29,833,555
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ARHGAP24 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgef37 |
Rho guanine nucleotide exchange factor 37 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of ARHGEF37 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
decreases expression |
ISO |
belinostat results in decreased expression of ARHGEF4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ARRB1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Asgr1 |
asialoglycoprotein receptor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of ASGR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
belinostat results in decreased expression of ASNS mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Astn1 |
astrotactin 1 |
decreases expression |
ISO |
belinostat results in decreased expression of ASTN1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ATP8B1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Aurka |
aurora kinase A |
decreases expression decreases activity |
ISO |
belinostat results in decreased expression of AURKA mRNA; belinostat results in decreased expression of AURKA protein belinostat results in decreased activity of AURKA protein |
CTD |
PMID:19606018 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
decreases activity decreases expression |
ISO |
belinostat results in decreased activity of AURKB protein belinostat results in decreased expression of AURKB mRNA; belinostat results in decreased expression of AURKB protein |
CTD |
PMID:19606018 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Aven |
apoptosis and caspase activation inhibitor |
decreases expression |
ISO |
belinostat results in decreased expression of AVEN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634
|
|
G |
B3galnt1 |
beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) |
decreases expression |
ISO |
belinostat results in decreased expression of B3GALNT1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332
|
|
G |
B3gnt5 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of B3GNT5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166
|
|
G |
Bag2 |
BAG cochaperone 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA belinostat results in increased expression of BAG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bbs9 |
Bardet-Biedl syndrome 9 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of BBS9 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:21,013,865...21,437,934
Ensembl chr 8:21,013,944...21,437,930
|
|
G |
Bcl11a |
BCL11 transcription factor A |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of BCL11A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of BCL2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
belinostat results in increased expression of BCL2L11 protein |
CTD |
PMID:18223231 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of BCLAF1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832
|
|
G |
Bfsp1 |
beaded filament structural protein 1 |
decreases expression |
ISO |
belinostat results in decreased expression of BFSP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:131,195,087...131,252,668
Ensembl chr 3:131,195,087...131,229,337
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
belinostat results in decreased expression of BIRC5 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA belinostat results in increased expression of BMP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Bmper |
BMP-binding endothelial regulator |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of BMPER mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
belinostat results in decreased expression of BMPR1B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Bnc2 |
basonuclin zinc finger protein 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA belinostat results in increased expression of BNC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:98,687,410...99,079,426
|
|
G |
Borcs8 |
BLOC-1 related complex subunit 8 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of BORCS8 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:19,274,305...19,280,969
Ensembl chr16:19,274,023...19,280,339
|
|
G |
Bspry |
B-box and SPRY domain containing |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
|
|
G |
C1h10orf143 |
similar to human chromosome 10 open reading frame 143 |
decreases expression |
ISO |
belinostat results in decreased expression of C10ORF143 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:192,184,440...192,222,676
Ensembl chr 1:192,184,445...192,222,398
|
|
G |
C1h19orf33 |
similar to human chromosome 19 open reading frame 33 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:84,549,830...84,550,666
Ensembl chr 1:84,549,831...84,550,664
|
|
G |
C2h4orf33 |
similar to human chromosome 4 open reading frame 33 |
increases expression |
ISO |
belinostat results in increased expression of C4ORF33 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:124,764,263...124,830,001
Ensembl chr 2:124,769,940...124,832,449
|
|
G |
C3h11orf96 |
similar to human chromosome 11 open reading frame 96 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of C11ORF96 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:79,920,129...79,921,523
|
|
G |
C5h8orf34 |
similar to human chromosome 8 open reading frame 34 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA belinostat results in increased expression of C8ORF34 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:7,238,853...7,776,769
|
|
G |
Cables1 |
Cdk5 and Abl enzyme substrate 1 |
decreases expression |
ISO |
belinostat results in decreased expression of CABLES1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:3,076,556...3,181,181
Ensembl chr18:3,075,524...3,181,181
|
|
G |
Cad |
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase |
decreases expression |
ISO |
belinostat results in decreased expression of CAD mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 6:25,292,133...25,315,078
Ensembl chr 6:25,292,133...25,319,861
|
|
G |
Calb1 |
calbindin 1 |
increases expression |
ISO |
belinostat results in increased expression of CALB1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calhm6 |
calcium homeostasis modulator family member 6 |
decreases expression |
ISO |
belinostat results in decreased expression of CALHM6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:26,095,591...26,097,336
Ensembl chr20:26,095,592...26,097,278
|
|
G |
Calml4 |
calmodulin-like 4 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of CALML4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:63,323,426...63,335,234
Ensembl chr 8:63,323,351...63,335,234
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
decreases expression |
ISO |
belinostat results in decreased expression of CAPRIN1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Car4 |
carbonic anhydrase 4 |
decreases expression |
ISO |
belinostat results in decreased expression of CA4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
decreases expression |
ISO |
belinostat results in decreased expression of CARD10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein] |
CTD |
PMID:18223231 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases cleavage |
ISO |
belinostat results in increased cleavage of CASP7 protein |
CTD |
PMID:25537862 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CASP8 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO |
belinostat results in increased cleavage of CASP9 protein Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein] |
CTD |
PMID:18223231 PMID:25537862 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccdc34 |
coiled-coil domain containing 34 |
increases expression |
ISO |
belinostat results in increased expression of CCDC34 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:96,553,074...96,588,310
Ensembl chr 3:96,552,992...96,588,146
|
|
G |
Ccdc69 |
coiled-coil domain containing 69 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CCDC69 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:39,173,282...39,200,358
Ensembl chr10:39,173,282...39,199,878
|
|
G |
Cckbr |
cholecystokinin B receptor |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of CCKBR mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CCL26 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
belinostat results in increased expression of CCN1 mRNA |
CTD |
PMID:23671600 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
belinostat results in increased expression of CCN2 mRNA |
CTD |
PMID:19606018 PMID:23671600 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
belinostat results in decreased expression of CCNA2 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
belinostat results in decreased expression of CCNB1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of CCND2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA belinostat results in increased expression of CD24 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd9 |
CD9 molecule |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CD9 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
ISO |
belinostat results in decreased expression of CDC25B mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
belinostat results in decreased expression of CDC25C mRNA |
CTD |
PMID:29733868 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CDH1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh18 |
cadherin 18 |
increases expression |
ISO |
belinostat results in increased expression of CDH18 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:72,818,076...73,820,144
Ensembl chr 2:73,345,005...73,820,138
|
|
G |
Cdh3 |
cadherin 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CDH3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdh9 |
cadherin 9 |
decreases expression increases expression |
ISO |
belinostat results in decreased expression of CDH9 mRNA belinostat results in increased expression of CDH9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:66,280,422...66,367,121
Ensembl chr 2:66,228,117...66,367,121
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
belinostat results in decreased expression of CDK1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
belinostat results in decreased expression of CDK4 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
belinostat promotes the reaction [decitabine results in increased expression of CDKN1A mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CDKN1A protein] belinostat results in increased expression of CDKN1A mRNA; belinostat results in increased expression of CDKN1A protein |
CTD |
PMID:19234609 PMID:19606018 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression |
ISO |
belinostat results in decreased expression of CDKN2A mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdx4 |
caudal type homeo box 4 |
decreases expression |
ISO |
belinostat results in decreased expression of CDX4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:68,326,874...68,335,461
Ensembl chr X:68,326,874...68,335,461
|
|
G |
Cep126 |
centrosomal protein 126 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CEP126 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:5,200,576...5,267,740
Ensembl chr 8:5,218,509...5,267,467
|
|
G |
Cep85l |
centrosomal protein 85-like |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CEP85L mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516
|
|
G |
Cfap119 |
cilia and flagella associated protein 119 |
increases expression |
ISO |
belinostat results in increased expression of CFAP119 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:182,197,171...182,216,936
Ensembl chr 1:182,192,947...182,202,338
|
|
G |
Cfap20dc |
CFAP20 domain containing |
increases expression |
ISO |
belinostat results in increased expression of CFAP20DC mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:16,231,248...16,476,978
Ensembl chr15:16,231,299...16,476,977
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases expression |
ISO |
belinostat results in decreased expression of CFTR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chga |
chromogranin A |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CHGA mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chodl |
chondrolectin |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA belinostat results in increased expression of CHODL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CHRM3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CHRNA3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chst15 |
carbohydrate sulfotransferase 15 |
increases expression |
ISO |
belinostat results in increased expression of CHST15 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707
|
|
G |
Cimap3 |
ciliary microtubule associated protein 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CIMAP3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:193,475,782...193,493,139
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA belinostat results in increased expression of CLDN7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Clrn1 |
clarin 1 |
increases expression |
ISO |
belinostat results in increased expression of CLRN1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:143,084,030...143,130,948
Ensembl chr 2:143,084,030...143,130,948
|
|
G |
Clrn3 |
clarin 3 |
decreases expression |
ISO |
belinostat results in decreased expression of CLRN3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:190,319,025...190,334,648
Ensembl chr 1:190,319,026...190,334,648
|
|
G |
Clu |
clusterin |
multiple interactions increases expression |
ISO |
belinostat promotes the reaction [decitabine results in increased expression of CLU mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CLU protein] belinostat results in increased expression of CLU mRNA; belinostat results in increased expression of CLU protein |
CTD |
PMID:19234609 PMID:19606018 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
decreases expression |
ISO |
belinostat results in decreased expression of CMPK2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555
|
|
G |
Cnmd |
chondromodulin |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CNMD mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:55,041,548...55,066,297
Ensembl chr15:55,041,561...55,066,297
|
|
G |
Cntn1 |
contactin 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CNTN1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cntn3 |
contactin 3 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of CNTN3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:134,841,268...135,214,460
Ensembl chr 4:134,842,266...135,125,613
|
|
G |
Cntnap4 |
contactin associated protein family member 4 |
decreases expression |
ISO |
belinostat results in decreased expression of CNTNAP4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:40,568,684...40,861,879
Ensembl chr19:40,568,684...40,854,656
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Coch |
cochlin |
decreases expression |
ISO |
belinostat results in decreased expression of COCH mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA belinostat results in increased expression of COL1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col26a1 |
collagen type XXVI alpha 1 chain |
decreases expression |
ISO |
belinostat results in decreased expression of COL26A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:19,792,693...19,938,556
Ensembl chr12:19,792,728...19,938,556
|
|
G |
Col6a6 |
collagen type VI alpha 6 chain |
decreases expression |
ISO |
belinostat results in decreased expression of COL6A6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:106,318,010...106,473,419
Ensembl chr 8:106,306,422...106,473,472
|
|
G |
Colec12 |
collectin sub-family member 12 |
increases expression |
ISO |
belinostat results in increased expression of COLEC12 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
|
|
G |
Colgalt2 |
collagen beta(1-O)galactosyltransferase 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of COLGALT2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:64,523,641...64,628,295
Ensembl chr13:64,523,658...64,627,549
|
|
G |
Comtd1 |
catechol-O-methyltransferase domain containing 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA belinostat results in increased expression of COMTD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:2,459,783...2,462,895
Ensembl chr15:2,459,783...2,462,895
|
|
G |
Cpne2 |
copine 2 |
decreases expression |
ISO |
belinostat results in decreased expression of CPNE2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:10,434,277...10,472,146
Ensembl chr19:10,434,277...10,471,820
|
|
G |
Cpne4 |
copine 4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA belinostat results in increased expression of CPNE4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068
|
|
G |
Cr1l |
complement C3b/C4b receptor 1 like |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CR1L mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:106,606,952...106,660,442
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Crb1 |
crumbs cell polarity complex component 1 |
increases expression |
ISO |
belinostat results in increased expression of CRB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:50,801,484...50,989,261
Ensembl chr13:50,800,959...50,989,261
|
|
G |
Crip1 |
cysteine rich protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA belinostat results in increased expression of CRIP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620
|
|
G |
Cripto |
cripto, EGF-CFC family member |
increases expression |
ISO |
belinostat results in increased expression of CRIPTO mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308
|
|
G |
Cryba4 |
crystallin, beta A4 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of CRYBA4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221
|
|
G |
Crybg1 |
crystallin beta-gamma domain containing 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CRYBG1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392
|
|
G |
Cthrc1 |
collagen triple helix repeat containing 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of CTHRC1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression |
ISO |
belinostat results in decreased expression of CTPS1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctsk |
cathepsin K |
decreases expression |
ISO |
belinostat results in decreased expression of CTSK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctso |
cathepsin O |
decreases expression |
ISO |
belinostat results in decreased expression of CTSO mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:167,230,330...167,253,702
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression decreases expression multiple interactions |
ISO |
belinostat results in increased expression of CXCL12 mRNA belinostat results in decreased expression of CXCL12 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
increases expression |
ISO |
belinostat results in increased expression of CXCL14 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cyfip1 |
cytoplasmic FMR1 interacting protein 1 |
decreases expression |
ISO |
belinostat results in decreased expression of CYFIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
belinostat results in increased expression of CYP1B1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
increases expression |
ISO |
belinostat results in increased expression of CYP26A1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
ISO |
belinostat results in increased expression of CYP39A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyth1 |
cytohesin 1 |
decreases expression |
ISO |
belinostat results in decreased expression of CYTH1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
|
|
G |
D430041D05Rikl |
RIKEN cDNA D430041D05 gene like |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of KIAA1549L mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:90,506,559...90,782,427
Ensembl chr 3:90,510,942...90,781,894
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DACT1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:89,790,644...89,817,906
|
|
G |
Dazl |
deleted in azoospermia-like |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA belinostat results in decreased expression of DAZL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:10,695,593...10,712,330
Ensembl chr 9:10,695,592...10,712,323
|
|
G |
Dcaf7 |
DDB1 and CUL4 associated factor 7 |
increases expression |
ISO |
belinostat results in increased expression of DCAF7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:90,974,095...90,996,275
Ensembl chr10:90,974,095...90,996,275
|
|
G |
Dcc |
DCC netrin 1 receptor |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
|
|
G |
Dcdc2 |
doublecortin domain containing 2 |
decreases expression |
ISO |
belinostat results in decreased expression of DCDC2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:39,845,952...40,031,781
Ensembl chr17:39,845,952...40,030,743
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
decreases expression |
ISO |
belinostat results in decreased expression of DDB2 mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
ISO |
belinostat results in decreased expression of DDC mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddx21 |
DExD-box helicase 21 |
decreases expression |
ISO |
belinostat results in decreased expression of DDX21 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr20:30,534,319...30,554,513
Ensembl chr20:30,534,319...30,554,543
|
|
G |
Defb1 |
defensin beta 1 |
decreases expression |
ISO |
belinostat results in decreased expression of DEFB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604
|
|
G |
Dennd1a |
DENN domain containing 1A |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of DENND1A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
|
|
G |
Depdc7 |
DEP domain containing 7 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DEPDC7 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DEPTOR mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dgki |
diacylglycerol kinase, iota |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA belinostat results in increased expression of DHRS2 mRNA |
CTD |
PMID:19606018 PMID:27188386 |
|
NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
|
|
G |
Diaph2 |
diaphanous-related formin 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DIAPH2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:92,395,189...93,234,521
Ensembl chr X:92,395,251...93,229,869
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases expression |
ISO |
belinostat results in decreased expression of DIO1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
belinostat results in increased expression of DKK1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
belinostat results in increased expression of DNAJB1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DNER mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dock10 |
dedicator of cytokinesis 10 |
decreases expression |
ISO |
belinostat results in decreased expression of DOCK10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525
|
|
G |
Dok5 |
docking protein 5 |
increases expression |
ISO |
belinostat results in increased expression of DOK5 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810
|
|
G |
Dppa2 |
developmental pluripotency-associated 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DPPA2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:52,549,024...52,556,740
|
|
G |
Dppa5 |
developmental pluripotency associated 5 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of DPPA5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:79,215,341...79,217,282
Ensembl chr 8:79,215,362...79,216,570 Ensembl chr 7:79,215,362...79,216,570
|
|
G |
Dtx3l |
deltex E3 ubiquitin ligase 3L |
decreases expression |
ISO |
belinostat results in decreased expression of DTX3L mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:64,814,926...64,824,539
Ensembl chr11:64,814,926...64,824,538
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
belinostat results in increased expression of DUSP10 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
decreases expression |
ISO |
belinostat results in decreased expression of DUSP9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821
|
|
G |
Dynlt5 |
dynein light chain Tctex-type family member 5 |
increases expression |
ISO |
belinostat results in increased expression of DYNLT5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:117,735,509...117,758,221
Ensembl chr 5:117,735,439...117,757,588
|
|
G |
E2f2 |
E2F transcription factor 2 |
decreases expression |
ISO |
belinostat results in decreased expression of E2F2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Eaf2 |
ELL associated factor 2 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Echdc2 |
enoyl CoA hydratase domain containing 2 |
decreases expression |
ISO |
belinostat results in decreased expression of ECHDC2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:122,916,134...122,934,859
|
|
G |
Edn1 |
endothelin 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of EDN1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of EDNRA mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA belinostat results in increased expression of EDNRB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
affects expression |
ISO |
belinostat affects the expression of EEF1A1 mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efcab2 |
EF-hand calcium binding domain 2 |
decreases expression |
ISO |
belinostat results in decreased expression of EFCAB2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:90,152,002...90,237,918
Ensembl chr13:90,152,185...90,238,218
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA belinostat results in increased expression of EFNA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
decreases expression |
ISO |
belinostat results in decreased expression of EIF4G2 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588
|
|
G |
Elmod1 |
ELMO domain containing 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ELMOD1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of ELOVL2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of EPB41L3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Epb41l5 |
erythrocyte membrane protein band 4.1 like 5 |
increases expression |
ISO |
belinostat results in increased expression of EPB41L5 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360
|
|
G |
Epcam |
epithelial cell adhesion molecule |
increases expression |
ISO |
belinostat results in increased expression of EPCAM mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Epdr1 |
ependymin related 1 |
decreases expression |
ISO |
belinostat results in decreased expression of EPDR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:45,333,932...45,358,597
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Epha1 |
Eph receptor A1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of EPHA1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
|
|
G |
Epha3 |
Eph receptor A3 |
increases expression |
ISO |
belinostat results in increased expression of EPHA3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Epha7 |
Eph receptor A7 |
increases expression |
ISO |
belinostat results in increased expression of EPHA7 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of EPHB2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Ermap |
erythroblast membrane associated protein (Scianna blood group) |
decreases expression |
ISO |
belinostat results in decreased expression of ERMAP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:132,788,847...132,803,030
Ensembl chr 5:132,789,991...132,802,847
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ETS1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
decreases expression |
ISO |
belinostat results in decreased expression of ETV5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215
|
|
G |
Exo1 |
exonuclease 1 |
decreases expression |
ISO |
belinostat results in decreased expression of EXO1 protein |
CTD |
PMID:29733868 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
increases expression |
ISO |
belinostat results in increased expression of EZH1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
F10 |
coagulation factor X |
decreases expression |
ISO |
belinostat results in decreased expression of F10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
increases expression |
ISO |
belinostat results in increased expression of F13A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
decreases expression multiple interactions increases expression |
ISO |
belinostat results in decreased expression of F2RL1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA belinostat results in increased expression of F2RL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
belinostat results in decreased expression of FABP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fam174b |
family with sequence similarity 174, member B |
decreases expression |
ISO |
belinostat results in decreased expression of FAM174B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:127,514,041...127,596,128 Ensembl chr 1:127,514,041...127,596,128
|
|
G |
Fam222a |
family with sequence similarity 222, member A |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of FAM222A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of FAM43A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
|
|
G |
Fancg |
FA complementation group G |
decreases expression |
ISO |
belinostat results in decreased expression of FANCG mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029
|
|
G |
Far2 |
fatty acyl CoA reductase 2 |
decreases expression |
ISO |
belinostat results in decreased expression of FAR2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:181,007,622...181,087,255
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of FBLN1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbln2 |
fibulin 2 |
decreases expression |
ISO |
belinostat results in decreased expression of FBLN2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G |
Fbln7 |
fibulin 7 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA belinostat results in decreased expression of FBLN7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:116,111,581...116,145,839
Ensembl chr 3:116,111,677...116,147,983
|
|
G |
Fbn1 |
fibrillin 1 |
decreases expression |
ISO |
belinostat results in decreased expression of FBN1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxo43 |
F-box protein 43 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of FBXO43 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:67,333,161...67,346,751
Ensembl chr 7:67,333,162...67,346,751
|
|
G |
Fbxw4 |
F-box and WD repeat domain containing 4 |
decreases expression |
ISO |
belinostat results in decreased expression of FBXW4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:244,426,896...244,514,163
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of FGF4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:200,023,937...200,027,793
Ensembl chr 1:200,024,056...200,025,466
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA belinostat results in decreased expression of FGF9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of FLT1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo5 |
flavin containing dimethylaniline monoxygenase 5 |
decreases expression |
ISO |
belinostat results in decreased expression of FMO5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:185,197,184...185,249,699
Ensembl chr 2:185,222,204...185,249,693
|
|
G |
Folr1 |
folate receptor alpha |
decreases expression |
ISO |
belinostat results in decreased expression of FOLR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
|
|
G |
Foxc2 |
forkhead box C2 |
increases expression |
ISO |
belinostat results in increased expression of FOXC2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Foxd3 |
forkhead box D3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of FOXD3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:114,335,084...114,337,450
Ensembl chr 5:114,335,408...114,336,817
|
|
G |
Foxh1 |
forkhead box H1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of FOXH1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:108,387,969...108,391,566
Ensembl chr 7:108,387,969...108,390,049
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA belinostat results in increased expression of FOXO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Frem1 |
Fras1 related extracellular matrix 1 |
decreases expression |
ISO |
belinostat results in decreased expression of FREM1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:97,321,266...97,469,523
Ensembl chr 5:97,322,538...97,469,543
|
|
G |
Frrs1l |
ferric-chelate reductase 1-like |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:71,659,284...71,690,108
|
|
G |
Fut9 |
fucosyltransferase 9 |
increases expression |
ISO |
belinostat results in increased expression of FUT9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:39,351,815...39,565,256
Ensembl chr 5:39,351,819...39,565,130
|
|
G |
Fzd5 |
frizzled class receptor 5 |
decreases expression |
ISO |
belinostat results in decreased expression of FZD5 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Fzd7 |
frizzled class receptor 7 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of FZD7 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GABRB3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GAD1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
belinostat results in increased expression of GADD45A mRNA; belinostat results in increased expression of GADD45A protein |
CTD |
PMID:29733868 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt17 |
polypeptide N-acetylgalactosaminyltransferase 17 |
decreases expression |
ISO |
belinostat results in decreased expression of GALNT17 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr12:25,323,230...25,781,897
Ensembl chr12:25,322,701...25,781,290
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA belinostat results in increased expression of GALNT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GAP43 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gata3 |
GATA binding protein 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GATA3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gba3 |
glucosylceramidase beta 3 |
decreases expression |
ISO |
belinostat results in decreased expression of GBA3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:60,574,974...60,721,411
Ensembl chr14:60,574,976...60,721,653
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
decreases expression |
ISO |
belinostat results in decreased expression of GBE1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
|
|
G |
Gcat |
glycine C-acetyltransferase |
decreases expression |
ISO |
belinostat results in decreased expression of GCAT mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:110,595,126...110,601,474
Ensembl chr 7:110,595,091...110,601,473
|
|
G |
Gdap1l1 |
ganglioside-induced differentiation-associated protein 1-like 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA belinostat results in decreased expression of GFRA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Glb1l3 |
galactosidase, beta 1-like 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GLB1L3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:25,179,165...25,220,904
Ensembl chr 8:25,179,165...25,220,904
|
|
G |
Gldn |
gliomedin |
increases expression |
ISO |
belinostat results in increased expression of GLDN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:54,679,119...54,723,196
|
|
G |
Glis3 |
GLIS family zinc finger 3 |
decreases expression |
ISO |
belinostat results in decreased expression of GLIS3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:225,976,029...226,395,849
Ensembl chr 1:225,976,326...226,395,899
|
|
G |
Glt8d2 |
glycosyltransferase 8 domain containing 2 |
decreases expression |
ISO |
belinostat results in decreased expression of GLT8D2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:21,029,534...21,081,081
Ensembl chr 7:21,029,525...21,081,080
|
|
G |
Gng11 |
G protein subunit gamma 11 |
increases expression |
ISO |
belinostat results in increased expression of GNG11 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442
|
|
G |
Gpc6 |
glypican 6 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of GPC6 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006
|
|
G |
Gpr143 |
G protein-coupled receptor 143 |
decreases expression |
ISO |
belinostat results in decreased expression of GPR143 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:22,002,914...22,027,720
Ensembl chr X:22,002,914...22,027,715
|
|
G |
Gpr27 |
G protein-coupled receptor 27 |
decreases expression |
ISO |
belinostat results in decreased expression of GPR27 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
decreases expression |
ISO |
belinostat results in decreased expression of GPX7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GREM1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Grhl3 |
grainyhead-like transcription factor 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of GRHL3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
increases expression |
ISO |
belinostat results in increased expression of GRIA3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
increases expression |
ISO |
belinostat results in increased expression of GRIK1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
decreases expression |
ISO |
belinostat results in decreased expression of GRK6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
belinostat results in increased phosphorylation of GSK3B protein |
CTD |
PMID:23671600 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
ISO |
belinostat results in increased expression of H1-0 mRNA |
CTD |
PMID:19606018 PMID:27188386 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
H1f10 |
H1.10 linker histone |
increases expression |
ISO |
belinostat results in increased expression of H1-10 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 4:120,440,515...120,441,578
Ensembl chr 4:120,440,870...120,441,448
|
|
G |
H2bc12 |
H2B clustered histone 12 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA belinostat results in decreased expression of H2BC12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:42,485,699...42,486,162
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA belinostat results in increased expression of HAPLN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Hapln4 |
hyaluronan and proteoglycan link protein 4 |
decreases expression |
ISO |
belinostat results in decreased expression of HAPLN4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:19,333,106...19,341,243
Ensembl chr16:19,333,106...19,341,243
|
|
G |
Hbe1 |
hemoglobin subunit epsilon 1 |
decreases expression |
ISO |
belinostat results in decreased expression of HBE1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:158,282,931...158,458,855
Ensembl chr 1:158,282,936...158,284,391
|
|
G |
Heg1 |
heart development protein with EGF-like domains 1 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of HEG1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA belinostat results in decreased expression of HES5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hesx1 |
HESX homeobox 1 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of HESX1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:2,191,852...2,193,957
Ensembl chr16:2,191,852...2,193,957
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA belinostat results in increased expression of HEY2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hgd |
homogentisate 1, 2-dioxygenase |
decreases expression |
ISO |
belinostat results in decreased expression of HGD mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323
|
|
G |
Hhex |
hematopoietically expressed homeobox |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of HHEX mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:42,707,954...42,708,420
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of H2BC5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hkdc1 |
hexokinase domain containing 1 |
decreases expression |
ISO |
belinostat results in decreased expression of HKDC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:30,335,322...30,373,792
Ensembl chr20:30,335,628...30,373,867
|
|
G |
Hmx2 |
H6 family homeobox 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of HMX2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:186,319,110...186,326,771
Ensembl chr 1:186,319,110...186,326,771
|
|
G |
Homer2 |
homer scaffold protein 2 |
decreases expression |
ISO |
belinostat results in decreased expression of HOMER2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:135,558,977...135,659,780
Ensembl chr 1:135,567,414...135,659,772
|
|
G |
Hoxd3 |
homeo box D3 |
increases expression |
ISO |
belinostat results in increased expression of HOXD3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:59,638,708...59,650,282
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hoxd4 |
homeo box D4 |
increases expression |
ISO |
belinostat results in increased expression of HOXD4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:59,614,464...59,634,042
Ensembl chr 3:59,614,464...59,631,528
|
|
G |
Hpdl |
4-hydroxyphenylpyruvate dioxygenase-like |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of HPDL mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:130,286,631...130,288,233
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases expression |
ISO |
belinostat results in increased expression of HPGD mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hpx |
hemopexin |
decreases expression |
ISO |
belinostat results in decreased expression of HPX mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Hunk |
hormonally upregulated Neu-associated kinase |
decreases expression |
ISO |
belinostat results in decreased expression of HUNK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526
|
|
G |
Hus1 |
HUS1 checkpoint clamp component |
increases expression |
ISO |
belinostat results in increased expression of HUS1 mRNA |
CTD |
PMID:29733868 |
|
NCBI chr14:83,688,702...83,703,466
Ensembl chr14:83,688,708...83,703,442
|
|
G |
Hyi |
hydroxypyruvate isomerase |
decreases expression |
ISO |
belinostat results in decreased expression of HYI mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:131,894,598...131,897,251
|
|
G |
Ice2 |
interactor of little elongation complex ELL subunit 2 |
increases expression |
ISO |
belinostat results in increased expression of ICE2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:70,043,419...70,085,217
Ensembl chr 8:70,043,424...70,084,995
|
|
G |
Id4 |
inhibitor of DNA binding 4 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ID4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of IDH3A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Idnk |
Idnk, gluconokinase |
decreases expression |
ISO |
belinostat results in decreased expression of IDNK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:6,483,575...6,490,780
Ensembl chr17:6,483,576...6,490,905
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
decreases expression |
ISO |
belinostat results in decreased expression of IFIT3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein] |
CTD |
PMID:29301935 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
increases expression |
ISO |
belinostat results in increased expression of IFNGR1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
belinostat results in increased expression of IGF1 mRNA |
CTD |
PMID:23671600 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
ISO |
belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein] |
CTD |
PMID:29301935 |
|
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il17d |
interleukin 17D |
decreases expression |
ISO |
belinostat results in decreased expression of IL17D mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:31,671,337...31,688,833
|
|
G |
Il17rb |
interleukin 17 receptor B |
decreases expression |
ISO |
belinostat results in decreased expression of IL17RB mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
|
|
G |
Il17rd |
interleukin 17 receptor D |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of IL17RD mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:2,228,438...2,295,122
Ensembl chr16:2,228,287...2,292,556
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of IL20RB mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Il4r |
interleukin 4 receptor |
decreases expression |
ISO |
belinostat results in decreased expression of IL4R mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
belinostat results in increased expression of IL6 mRNA |
CTD |
PMID:23671600 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Impg1 |
interphotoreceptor matrix proteoglycan 1 |
increases expression |
ISO |
belinostat results in increased expression of IMPG1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:81,243,624...81,389,722
Ensembl chr 8:81,243,624...81,389,722
|
|
G |
Incenp |
inner centromere protein |
decreases expression |
ISO |
belinostat results in decreased expression of INCENP mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of INHBA mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inpp1 |
inositol polyphosphate-1-phosphatase |
decreases expression |
ISO |
belinostat results in decreased expression of INPP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:48,688,037...48,717,793
Ensembl chr 9:48,669,901...48,717,793
|
|
G |
Irx1 |
iroquois homeobox 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of IRX1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:31,294,615...31,300,444
|
|
G |
Irx2 |
iroquois homeobox 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of IRX2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:30,660,960...30,666,378
Ensembl chr 1:30,660,960...30,666,378
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression |
ISO |
belinostat results in increased expression of ITGA2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itga3 |
integrin subunit alpha 3 |
decreases expression |
ISO |
belinostat results in decreased expression of ITGA3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgb5 |
integrin subunit beta 5 |
decreases expression |
ISO |
belinostat results in decreased expression of ITGB5 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ITIH5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
|
|
G |
Itm2a |
integral membrane protein 2A |
increases expression |
ISO |
belinostat results in increased expression of ITM2A mRNA |
CTD |
PMID:26272509 |
|
NCBI chr X:72,486,383...72,492,344
Ensembl chr X:72,486,381...72,492,363
|
|
G |
Itpripl2 |
ITPRIP like 2 |
decreases expression |
ISO |
belinostat results in decreased expression of ITPRIPL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:172,796,849...172,802,950
|
|
G |
Jazf1 |
JAZF zinc finger 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:81,879,501...82,183,237
Ensembl chr 4:81,881,061...82,183,100
|
|
G |
Kansl1l |
KAT8 regulatory NSL complex subunit 1-like |
decreases expression |
ISO |
belinostat results in decreased expression of KANSL1L mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:68,211,151...68,316,992
Ensembl chr 9:68,211,189...68,300,222
|
|
G |
Kcnj13 |
potassium inwardly-rectifying channel, subfamily J, member 13 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of KCNJ13 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
decreases expression |
ISO |
belinostat results in decreased expression of KCNJ2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
|
|
G |
Kdm4c |
lysine demethylase 4C |
increases expression |
ISO |
belinostat results in increased expression of KDM4C mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:88,100,710...88,306,821
Ensembl chr 5:88,100,733...88,306,818
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of KDR mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
ISO |
belinostat results in decreased expression of KEAP1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kiaa0040 |
KIAA0040 ortholog |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of KIAA0040 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:72,274,519...72,312,103
Ensembl chr13:72,274,552...72,312,103
|
|
G |
Klf5 |
KLF transcription factor 5 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of KLF5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf9 |
KLF transcription factor 9 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Klhl18 |
kelch-like family member 18 |
increases expression |
ISO |
belinostat results in increased expression of KLHL18 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:110,400,679...110,459,442
Ensembl chr 8:110,400,681...110,459,323
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
decreases expression |
ISO |
belinostat results in decreased expression of KPNB1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
|
|
G |
Krt18 |
keratin 18 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of KRT18 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lactb |
lactamase, beta |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA belinostat results in increased expression of LACTB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539
|
|
G |
Lama4 |
laminin subunit alpha 4 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of LAMA4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Lctl |
lactase-like |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of LCTL mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:64,618,356...64,654,851
Ensembl chr 8:64,618,350...64,639,357
|
|
G |
Lgi1 |
leucine-rich, glioma inactivated 1 |
increases expression |
ISO |
belinostat results in increased expression of LGI1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:236,043,269...236,084,617
Ensembl chr 1:236,042,954...236,084,616
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of LHX2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
|
|
G |
Lhx8 |
LIM homeobox 8 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of LHX8 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:243,244,958...243,269,624
Ensembl chr 2:243,244,961...243,269,416
|
|
G |
Lifr |
LIF receptor subunit alpha |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of LIMCH1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
G |
Lman1 |
lectin, mannose-binding, 1 |
decreases expression |
ISO |
belinostat results in decreased expression of LMAN1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
|
|
G |
Lmo2 |
LIM domain only 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of LMO2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:90,355,234...90,377,970
Ensembl chr 3:90,365,883...90,377,953
|
|
G |
Lmo3 |
LIM domain only 3 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of LMO3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222
|
|
G |
LOC100912195 |
protein BEX1-like |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of BEX5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:110,047,861...110,051,812
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of LPAR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
increases expression |
ISO |
belinostat results in increased expression of LPAR6 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G |
Lrrc10b |
leucine rich repeat containing 10B |
decreases expression |
ISO |
belinostat results in decreased expression of LRRC10B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:207,096,471...207,097,699
Ensembl chr 1:207,022,919...207,098,045
|
|
G |
Lrrc17 |
leucine rich repeat containing 17 |
increases expression |
ISO |
belinostat results in increased expression of LRRC17 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845
|
|
G |
Lrrc55 |
leucine rich repeat containing 55 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA belinostat results in decreased expression of LRRC55 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:70,269,908...70,280,651
Ensembl chr 3:70,265,936...70,278,639
|
|
G |
Lrrn3 |
leucine rich repeat neuronal 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of LRRN3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
|
|
G |
LRRTM1 |
leucine rich repeat transmembrane neuronal 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of LRRTM1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:109,701,815...109,718,924
Ensembl chr 4:109,701,815...109,717,184
|
|
G |
Lyzl6 |
lysozyme-like 6 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA belinostat results in increased expression of LYZL6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:88,544,342...88,549,177
Ensembl chr10:88,544,342...88,549,177
|
|
G |
Macc1 |
MET transcriptional regulator MACC1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MACC1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255
|
|
G |
Macroh2a1 |
macroH2A.1 histone |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA belinostat results in decreased expression of MACROH2A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072
|
|
G |
Magi2 |
membrane associated guanylate kinase, WW and PDZ domain containing 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MAGI2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
belinostat results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:19606018 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
belinostat results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
increases expression |
ISO |
belinostat results in increased expression of MAP3K8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216
|
|
G |
Map6 |
microtubule-associated protein 6 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of MAP6 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Map7d2 |
MAP7 domain containing 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of MAP7D2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:35,372,453...35,488,073
Ensembl chr X:35,372,700...35,488,091
|
|
G |
Marveld1 |
MARVEL domain containing 1 |
decreases expression |
ISO |
belinostat results in decreased expression of MARVELD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:240,954,452...240,958,384
|
|
G |
Mbnl3 |
muscleblind-like splicing regulator 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MBNL3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:130,641,942...130,737,179
Ensembl chr X:130,648,538...130,737,056
|
|
G |
Mchr1 |
melanin-concentrating hormone receptor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of MCHR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
ISO |
belinostat results in decreased expression of MCM3 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
belinostat results in decreased expression of MCM7 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mcoln3 |
mucolipin TRP cation channel 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MCOLN3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:234,966,010...235,043,047
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MEOX1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
|
|
G |
Mettl7b |
methyltransferase like 7B |
decreases expression |
ISO |
belinostat results in decreased expression of TMT1B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:1,388,876...1,391,526
Ensembl chr 7:1,388,879...1,391,526
|
|
G |
Mfng |
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of MFNG mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653
|
|
G |
Mgam |
maltase-glucoamylase |
decreases expression |
ISO |
belinostat results in decreased expression of MGAM mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:69,441,626...69,602,068
Ensembl chr 4:69,446,150...69,692,715
|
|
G |
Miat |
myocardial infarction associated transcript |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of MIAT mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:44,414,620...44,429,852
|
|
G |
Mlana |
melan-A |
decreases expression |
ISO |
belinostat results in decreased expression of MLANA mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343
|
|
G |
Mlh1 |
mutL homolog 1 |
multiple interactions |
ISO |
belinostat promotes the reaction [decitabine results in increased expression of MLH1 protein] |
CTD |
PMID:19259094 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
increases expression |
ISO |
belinostat results in increased expression of MPG mRNA |
CTD |
PMID:29733868 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mpped2 |
metallophosphoesterase domain containing 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of MPPED2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:93,180,895...93,355,605
Ensembl chr 3:93,181,167...93,355,618
|
|
G |
Msx1 |
msh homeobox 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MSX1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:72,961,036...72,964,970
Ensembl chr14:72,961,148...72,964,966
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA belinostat results in increased expression of MSX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mthfs |
methenyltetrahydrofolate synthetase |
decreases expression |
ISO |
belinostat results in decreased expression of MTHFS mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:89,729,498...89,801,998
Ensembl chr 8:89,729,508...89,799,089
|
|
G |
Muc15 |
mucin 15, cell surface associated |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA belinostat results in increased expression of MUC15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:97,294,728...97,308,641
Ensembl chr 3:97,294,783...97,307,090
|
|
G |
Mylip |
myosin regulatory light chain interacting protein |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of MYLIP mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295
|
|
G |
Mylk |
myosin light chain kinase |
decreases expression |
ISO |
belinostat results in decreased expression of MYLK mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myo3b |
myosin IIIB |
increases expression |
ISO |
belinostat results in increased expression of MYO3B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:54,820,225...55,228,518
Ensembl chr 3:54,820,251...55,227,373
|
|
G |
Myof |
myoferlin |
increases expression |
ISO |
belinostat results in increased expression of MYOF mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nanog |
Nanog homeobox |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NANOG mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nanos1 |
nanos C2HC-type zinc finger 1 |
decreases expression |
ISO |
belinostat results in decreased expression of NANOS1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:259,897,663...259,901,561
Ensembl chr 1:259,897,939...259,898,730
|
|
G |
Nav3 |
neuron navigator 3 |
increases expression |
ISO |
belinostat results in increased expression of NAV3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698
|
|
G |
Ncald |
neurocalcin delta |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NCALD mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
belinostat results in decreased expression of NCAN mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NDP mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934
|
|
G |
Nefl |
neurofilament light chain |
increases expression |
ISO |
belinostat results in increased expression of NEFL mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Negr1 |
neuronal growth regulator 1 |
increases expression |
ISO |
belinostat results in increased expression of NEGR1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:245,624,435...246,356,730
|
|
G |
Nell2 |
neural EGFL like 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NELL2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:126,343,089...126,662,903
Ensembl chr 7:126,198,851...126,733,503
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NETO2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:21,344,299...21,415,524
Ensembl chr19:21,344,289...21,417,023
|
|
G |
Nexmif |
neurite extension and migration factor |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:69,088,076...69,219,253
Ensembl chr X:69,088,076...69,112,930
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases expression |
ISO |
Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein] |
CTD |
PMID:18223231 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NFKBIA protein Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein] |
CTD |
PMID:18223231 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Nipal2 |
NIPA-like domain containing 2 |
decreases expression |
ISO |
belinostat results in decreased expression of NIPAL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:65,774,477...65,884,807
|
|
G |
Nlgn3 |
neuroligin 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA belinostat results in decreased expression of NLGN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:66,427,926...66,457,378
Ensembl chr X:66,429,458...66,451,876
|
|
G |
Nme8 |
NME/NM23 family member 8 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA belinostat results in increased expression of NME8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:45,237,022...45,304,948
Ensembl chr17:45,238,120...45,304,948
|
|
G |
Nmi |
N-myc (and STAT) interactor |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NMI mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Noct |
nocturnin |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nog |
noggin |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NOG mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EOLA2-DT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH11Y mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO1B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nol4 |
nucleolar protein 4 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NOL4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:13,932,499...14,294,873
Ensembl chr18:13,932,510...14,296,286
|
|
G |
Npffr2 |
neuropeptide FF receptor 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NPFFR2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:18,513,120...18,558,074
Ensembl chr14:18,513,277...18,521,919
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
increases expression |
ISO |
belinostat results in increased expression of NPR3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
|
|
G |
Npy |
neuropeptide Y |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NPY mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA belinostat results in increased expression of NQO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nrp1 |
neuropilin 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of NRP1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nrxn2 |
neurexin 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NRXN2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsun7 |
NOP2/Sun RNA methyltransferase family member 7 |
decreases expression |
ISO |
belinostat results in decreased expression of NSUN7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:41,878,562...41,935,238
Ensembl chr14:41,879,293...41,934,949
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
increases expression |
ISO |
belinostat results in increased expression of NTRK3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of NUCB2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Nudt12 |
nudix hydrolase 12 |
increases expression |
ISO |
belinostat results in increased expression of NUDT12 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:98,741,627...98,755,039
Ensembl chr 9:98,742,360...98,755,039
|
|
G |
Nwd2 |
NACHT and WD repeat domain containing 2 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:44,480,049...44,671,417
Ensembl chr14:44,482,287...44,670,299
|
|
G |
Nxph2 |
neurexophilin 2 |
decreases expression |
ISO |
belinostat results in decreased expression of NXPH2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:5,986,175...5,988,525
Ensembl chr 3:5,756,621...5,987,008
|
|
G |
Ociad2 |
OCIA domain containing 2 |
decreases expression |
ISO |
belinostat results in decreased expression of OCIAD2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:34,873,668...34,889,276
Ensembl chr14:34,873,820...34,889,265
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
ISO |
belinostat results in increased expression of ODC1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression |
ISO |
belinostat results in decreased expression of OGG1 mRNA; belinostat results in decreased expression of OGG1 protein |
CTD |
PMID:29733868 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Olfm3 |
olfactomedin 3 |
increases expression |
ISO |
belinostat results in increased expression of OLFM3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:202,729,610...202,952,120
Ensembl chr 2:202,729,936...202,952,112
|
|
G |
Olfml3 |
olfactomedin-like 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of OLFML3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050
|
|
G |
Oplah |
5-oxoprolinase (ATP-hydrolysing) |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:108,011,472...108,051,751
Ensembl chr 7:108,011,475...108,035,297
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
decreases expression |
ISO |
belinostat results in decreased expression of PA2G4 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases expression |
ISO |
belinostat results in increased cleavage of PARP1 protein Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein] belinostat results in increased expression of PARP1 mRNA; belinostat results in increased expression of PARP1 protein |
CTD |
PMID:18223231 PMID:25537862 PMID:29733868 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp9 |
poly (ADP-ribose) polymerase family, member 9 |
decreases expression |
ISO |
belinostat results in decreased expression of PARP9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:64,780,977...64,814,995
Ensembl chr11:64,780,981...64,815,455
|
|
G |
Parvb |
parvin, beta |
decreases expression |
ISO |
belinostat results in decreased expression of PARVB mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:115,360,261...115,445,766
|
|
G |
Pax3 |
paired box 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PAX3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Pax7 |
paired box 7 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PAX7 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:151,996,368...152,098,023
Ensembl chr 5:151,999,092...152,097,979
|
|
G |
Pbx2 |
PBX homeobox 2 |
decreases expression |
ISO |
belinostat results in decreased expression of PBX2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425
|
|
G |
Pcdh10 |
protocadherin 10 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PCDH10 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:128,617,174...128,677,190
|
|
G |
Pcdh7 |
protocadherin 7 |
decreases expression |
ISO |
belinostat results in decreased expression of PCDH7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
|
|
G |
Pcdh8 |
protocadherin 8 |
increases expression |
ISO |
belinostat results in increased expression of PCDH8 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:55,198,470...55,203,039
Ensembl chr15:55,198,459...55,205,872
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
ISO |
belinostat results in decreased expression of PCSK9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pde10a |
phosphodiesterase 10A |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of PDE10A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde7b |
phosphodiesterase 7B |
increases expression |
ISO |
belinostat results in increased expression of PDE7B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
multiple interactions decreases expression increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA belinostat results in decreased expression of PDGFA mRNA belinostat results in increased expression of PDGFA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdlim1 |
PDZ and LIM domain 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA belinostat results in increased expression of PDLIM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076
|
|
G |
Pdpn |
podoplanin |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PDPN mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
|
|
G |
Peg10 |
paternally expressed 10 |
increases expression |
ISO |
belinostat results in increased expression of PEG10 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pex13 |
peroxisomal biogenesis factor 13 |
increases expression |
ISO |
belinostat results in increased expression of PEX13 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:97,602,829...97,621,233
Ensembl chr14:97,603,539...97,621,262
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
belinostat results in increased expression of PHLDA1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Phlda2 |
pleckstrin homology-like domain, family A, member 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PHLDA2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836
|
|
G |
Piezo1 |
piezo-type mechanosensitive ion channel component 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA belinostat results in decreased expression of PIEZO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
belinostat results in increased expression of PIM1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
|
|
G |
Pipox |
pipecolic acid and sarcosine oxidase |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PIPOX mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:62,769,874...62,783,484
Ensembl chr10:62,769,900...62,782,370
|
|
G |
Pitx2 |
paired-like homeodomain 2 |
increases expression |
ISO |
belinostat results in increased expression of PITX2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
|
|
G |
Pkdcc |
protein kinase domain containing, cytoplasmic |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PKDCC mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:11,455,686...11,465,002
Ensembl chr 6:11,455,686...11,465,556
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PLA2G2A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PLA2G4A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plaat3 |
phospholipase A and acyltransferase 3 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:204,782,608...204,816,397
Ensembl chr 1:204,782,729...204,817,667
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PLAU mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plce1 |
phospholipase C, epsilon 1 |
decreases expression |
ISO |
belinostat results in decreased expression of PLCE1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438
|
|
G |
Pld5 |
phospholipase D family, member 5 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of PLD5 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:87,895,694...88,232,868
Ensembl chr13:87,896,369...88,232,868
|
|
G |
Plekha2 |
pleckstrin homology domain containing A2 |
decreases expression |
ISO |
belinostat results in decreased expression of PLEKHA2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:66,938,684...67,000,661
Ensembl chr16:66,939,109...66,999,395
|
|
G |
Plg |
plasminogen |
decreases expression |
ISO |
belinostat results in decreased expression of PLG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
|
|
G |
Plpp5 |
phospholipid phosphatase 5 |
decreases expression |
ISO |
belinostat results in decreased expression of PLPP5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:66,349,483...66,353,887
Ensembl chr16:66,349,502...66,464,797
|
|
G |
Plxnc1 |
plexin C1 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of PLXNC1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
decreases expression |
ISO |
belinostat results in decreased expression of PNLIPRP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
G |
Pnma2 |
PNMA family member 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of PNMA2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:41,111,942...41,119,649
Ensembl chr15:41,112,009...41,121,427
|
|
G |
Podxl |
podocalyxin-like |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PODXL mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Polr3g |
RNA polymerase III subunit G |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of POLR3G mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:11,945,215...11,986,125
Ensembl chr 2:11,945,217...11,986,125
|
|
G |
Pou2f3 |
POU class 2 homeobox 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA belinostat results in increased expression of POU2F3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:43,495,408...43,577,795
Ensembl chr 8:43,495,527...43,577,795
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
belinostat results in increased expression of POU5F1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pou6f2 |
POU class 6 homeobox 2 |
increases expression |
ISO |
belinostat results in increased expression of POU6F2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:46,472,182...46,886,796
Ensembl chr17:46,472,181...46,921,039
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PPARGC1B mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppic |
peptidylprolyl isomerase C |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PPIC mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:46,842,410...46,855,016
Ensembl chr18:46,842,409...46,855,017
|
|
G |
Ppm1k |
protein phosphatase, Mg2+/Mn2+ dependent, 1K |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PPM1K mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:87,612,204...87,636,152
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
belinostat results in increased expression of PPP1R15A mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Ppp1r3b |
protein phosphatase 1, regulatory subunit 3B |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PPP1R3B mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:56,830,011...56,842,395
Ensembl chr16:56,829,660...56,842,406
|
|
G |
Ppp4r4 |
protein phosphatase 4, regulatory subunit 4 |
increases expression |
ISO |
belinostat results in increased expression of PPP4R4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:122,663,172...122,753,988
Ensembl chr 6:122,663,344...122,753,384
|
|
G |
Prdm14 |
PR/SET domain 14 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PRDM14 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:6,082,163...6,092,712
Ensembl chr 5:6,082,442...6,092,712
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of PRKACA mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prr15 |
proline rich 15 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436
|
|
G |
Prss23 |
serine protease 23 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of PRSS23 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Pstk |
phosphoseryl-tRNA kinase |
decreases expression |
ISO |
belinostat results in decreased expression of PSTK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:186,157,730...186,168,145
Ensembl chr 1:186,157,707...186,168,145
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4A3 |
decreases expression |
ISO |
belinostat results in decreased expression of PTP4A3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919
|
|
G |
Ptpn3 |
protein tyrosine phosphatase, non-receptor type 3 |
decreases expression |
ISO |
belinostat results in decreased expression of PTPN3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
decreases expression |
ISO |
belinostat results in decreased expression of PTPN5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
|
|
G |
Ptx3 |
pentraxin 3 |
decreases expression |
ISO |
belinostat results in decreased expression of PTX3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Pyroxd2 |
pyridine nucleotide-disulphide oxidoreductase domain 2 |
decreases expression |
ISO |
belinostat results in decreased expression of PYROXD2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:241,523,278...241,549,083
Ensembl chr 1:241,523,377...241,548,761
|
|
G |
Rab29 |
RAB29, member RAS oncogene family |
increases expression |
ISO |
belinostat results in increased expression of RAB29 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378
|
|
G |
Rab3c |
RAB3C, member RAS oncogene family |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RAB3C mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:41,627,720...41,843,749
|
|
G |
Rab3ip |
RAB3A interacting protein |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:52,531,461...52,575,295
Ensembl chr 7:52,532,401...52,561,043
|
|
G |
Rabgap1l |
RAB GTPase activating protein 1-like |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RABGAP1L mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
belinostat results in decreased expression of RAC1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rad17 |
RAD17 checkpoint clamp loader component |
decreases expression |
ISO |
belinostat results in decreased expression of RAD17 mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:31,764,261...31,794,072
|
|
G |
Rad18 |
RAD18 E3 ubiquitin protein ligase |
decreases expression |
ISO |
belinostat results in decreased expression of RAD18 mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069
|
|
G |
Rad51c |
RAD51 paralog C |
decreases expression |
ISO |
belinostat results in decreased expression of RAD51C mRNA; belinostat results in decreased expression of RAD51C protein |
CTD |
PMID:29733868 |
|
NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
|
|
G |
Rad9a |
RAD9 checkpoint clamp component A |
decreases expression |
ISO |
belinostat results in decreased expression of RAD9A mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 1:201,488,511...201,553,582
Ensembl chr 1:201,487,136...201,553,608
|
|
G |
Ran |
RAN, member RAS oncogene family |
decreases expression |
ISO |
belinostat results in decreased expression of RAN mRNA |
CTD |
PMID:19606018 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rarres1 |
retinoic acid receptor responder 1 |
decreases expression |
ISO |
belinostat results in decreased expression of RARRES1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:151,749,715...151,783,975
Ensembl chr 2:151,749,715...151,783,978
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RARRES2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rasef |
RAS and EF hand domain containing |
increases expression |
ISO |
belinostat results in increased expression of RASEF mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:87,548,908...87,619,031
|
|
G |
Rax |
retina and anterior neural fold homeobox |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of RAX mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:59,463,347...59,467,469
Ensembl chr18:59,463,737...59,467,431
|
|
G |
Rbfox3 |
RNA binding fox-1 homolog 3 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of RBFOX3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935
|
|
G |
Rcbtb2 |
RCC1 and BTB domain containing protein 2 |
decreases expression |
ISO |
belinostat results in decreased expression of RCBTB2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:48,319,809...48,364,441
Ensembl chr15:48,323,866...48,383,750
|
|
G |
Rcc2 |
regulator of chromosome condensation 2 |
decreases expression |
ISO |
belinostat results in decreased expression of RCC2 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 5:152,994,406...153,017,223
Ensembl chr 5:152,993,665...153,017,205
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases acetylation |
ISO |
Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein] |
CTD |
PMID:18223231 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Reln |
reelin |
increases expression |
ISO |
belinostat results in increased expression of RELN mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
|
|
G |
Rev1 |
REV1, DNA directed polymerase |
decreases expression |
ISO |
belinostat results in decreased expression of REV1 mRNA |
CTD |
PMID:29733868 |
|
NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576
|
|
G |
Rhob |
ras homolog family member B |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RHOB mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rnf144b |
ring finger protein 144B |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RNF144B mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:17,431,271...17,580,687
Ensembl chr17:17,432,786...17,562,760
|
|
G |
Rnf150 |
ring finger protein 150 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RNF150 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:25,006,978...25,229,273
Ensembl chr19:25,006,611...25,228,678
|
|
G |
Rnf180 |
ring finger protein 180 |
decreases expression |
ISO |
belinostat results in decreased expression of RNF180 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:36,330,285...36,511,168
Ensembl chr 2:36,330,292...36,512,614
|
|
G |
Rnf217 |
ring finger protein 217 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA belinostat results in increased expression of RNF217 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:26,015,728...26,108,736
|
|
G |
Robo2 |
roundabout guidance receptor 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of ROBO2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536
|
|
G |
Rph3al |
rabphilin 3A-like (without C2 domains) |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:60,689,943...60,833,354
Ensembl chr10:60,690,031...60,801,883
|
|
G |
Rsl1d1 |
ribosomal L1 domain containing 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:4,424,868...4,436,753
Ensembl chr10:4,397,821...4,439,593
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of HLA-DMB mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
G |
RT1-Ha |
RT1 class II, locus Ha |
decreases expression |
ISO |
belinostat results in decreased expression of HLA-DPA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA belinostat results in decreased expression of RTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rtp1 |
receptor (chemosensory) transporter protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:77,422,982...77,425,498
Ensembl chr11:77,422,982...77,425,498
|
|
G |
Runx1t1 |
RUNX1 partner transcriptional co-repressor 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of RUNX1T1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of S100A10 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of S1PR3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA belinostat results in increased expression of SAT1 mRNA |
CTD |
PMID:19606018 PMID:26272509 PMID:27188386 |
|
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
|
|
G |
Scg3 |
secretogranin III |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SCG3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scgb3a2 |
secretoglobin, family 3A, member 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA belinostat results in increased expression of SCGB3A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:35,932,840...35,935,762
Ensembl chr18:35,932,840...35,935,762
|
|
G |
Sclt1 |
sodium channel and clathrin linker 1 |
increases expression |
ISO |
belinostat results in increased expression of SCLT1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:124,605,445...124,763,964
Ensembl chr 2:124,605,658...124,764,065
|
|
G |
Scml1 |
Scm polycomb group protein like 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA belinostat results in increased expression of SCML1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:32,893,100...32,912,686
Ensembl chr X:32,894,327...32,911,366
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SCNN1A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181
|
|
G |
Sdsl |
serine dehydratase-like |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of SDSL mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:36,099,693...36,109,914
Ensembl chr12:36,099,693...36,109,906
|
|
G |
Sema3b |
semaphorin 3B |
decreases expression |
ISO |
belinostat results in decreased expression of SEMA3B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:108,271,663...108,280,326
Ensembl chr 8:108,271,666...108,282,919
|
|
G |
Sema3c |
semaphorin 3C |
increases expression |
ISO |
belinostat results in increased expression of SEMA3C mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534
|
|
G |
Sema3e |
semaphorin 3E |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SEMA3E mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:20,297,534...20,555,287
Ensembl chr 4:20,299,718...20,555,229
|
|
G |
Sema3f |
semaphorin 3F |
decreases expression |
ISO |
belinostat results in decreased expression of SEMA3F mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:108,357,629...108,386,569
Ensembl chr 8:108,357,629...108,387,083
|
|
G |
Sema6d |
semaphorin 6D |
decreases expression |
ISO |
belinostat results in decreased expression of SEMA6D mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:111,883,872...111,941,094
|
|
G |
Septin6 |
septin 6 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SEPTIN6 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:116,153,255...116,230,334
Ensembl chr X:116,153,255...116,230,115
|
|
G |
Serpina1 |
serpin family A member 1 |
decreases expression |
ISO |
belinostat results in decreased expression of SERPINA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
|
|
G |
Serpina7 |
serpin family A member 7 |
decreases expression |
ISO |
belinostat results in decreased expression of SERPINA7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Serpinb1a |
serpin family B member 1A |
decreases expression |
ISO |
belinostat results in decreased expression of SERPINB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
|
|
G |
Serpinb9 |
serpin family B member 9 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SERPINB9 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
|
|
G |
Serpini1 |
serpin family I member 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SERPINI1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135
|
|
G |
Sesn3 |
sestrin 3 |
increases expression |
ISO |
belinostat results in increased expression of SESN3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842
|
|
G |
Sez6 |
seizure related 6 homolog |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SEZ6 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:62,818,931...62,868,686
Ensembl chr10:62,819,069...62,868,671
|
|
G |
Sfmbt2 |
Scm-like with four mbt domains 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SFMBT2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:67,934,296...68,128,905
Ensembl chr17:67,935,904...68,128,781
|
|
G |
Sgk3 |
serum/glucocorticoid regulated kinase family, member 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SGK3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476
|
|
G |
Shc3 |
SHC adaptor protein 3 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:13,652,247...13,772,710
Ensembl chr17:13,651,202...13,772,710
|
|
G |
Shisal1 |
shisa like 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA belinostat results in decreased expression of SHISAL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:115,506,947...115,611,518
Ensembl chr 7:115,509,035...115,575,449
|
|
G |
Shroom1 |
shroom family member 1 |
decreases expression |
ISO |
belinostat results in decreased expression of SHROOM1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:37,621,149...37,631,895
Ensembl chr10:37,621,723...37,631,256
|
|
G |
Siae |
sialic acid acetylesterase |
increases expression |
ISO |
belinostat results in increased expression of SIAE mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:37,318,724...37,354,004
Ensembl chr 8:37,318,747...37,353,996
|
|
G |
Six3 |
SIX homeobox 3 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of SIX3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:9,039,017...9,043,336
Ensembl chr 6:9,036,434...9,053,301
|
|
G |
Six6os1 |
Six6 opposite strand transcript 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA belinostat results in decreased expression of C14ORF39 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:91,579,185...91,615,183
Ensembl chr 6:91,579,325...91,615,148
|
|
G |
Skap2 |
src kinase associated phosphoprotein 2 |
increases expression |
ISO |
belinostat results in increased expression of SKAP2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
|
|
G |
Slc16a14 |
solute carrier family 16, member 14 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA belinostat results in decreased expression of SLC16A14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc25a21 |
solute carrier family 25 member 21 |
decreases expression |
ISO |
belinostat results in decreased expression of SLC25A21 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:74,203,439...74,702,902
Ensembl chr 6:74,203,440...74,702,680
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc35d3 |
solute carrier family 35, member D3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SLC35D3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:14,565,482...14,573,581
Ensembl chr 1:14,569,687...14,573,159
|
|
G |
Slc35f3 |
solute carrier family 35, member F3 |
decreases expression |
ISO |
belinostat results in decreased expression of SLC35F3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:54,102,811...54,371,765
Ensembl chr19:54,103,120...54,372,839
|
|
G |
Slc38a4 |
solute carrier family 38, member 4 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SLC38A4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
|
|
G |
Slc38a6 |
solute carrier family 38, member 6 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SLC38A6 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:91,987,672...92,049,935
|
|
G |
Slc43a1 |
solute carrier family 43 member 1 |
increases expression |
ISO |
belinostat results in increased expression of SLC43A1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:69,920,586...69,946,768
Ensembl chr 3:69,920,649...69,946,768
|
|
G |
Slc44a3 |
solute carrier family 44, member 3 |
decreases expression |
ISO |
belinostat results in decreased expression of SLC44A3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:209,552,138...209,628,182
Ensembl chr 2:209,552,144...209,629,044
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
increases expression |
ISO |
belinostat results in increased expression of SLC6A2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
belinostat results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slc9b2 |
solute carrier family 9 member B2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of SLC9B2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:223,726,982...223,761,234
Ensembl chr 2:223,736,354...223,761,225
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SLCO4C1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715
|
|
G |
Slfn4 |
schlafen family member 4 |
increases expression |
ISO |
belinostat results in increased expression of SLFN12 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:67,994,601...68,018,141
Ensembl chr10:68,000,028...68,018,138 Ensembl chr10:68,000,028...68,018,138
|
|
G |
Slit1 |
slit guidance ligand 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SLIT1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
|
|
G |
Slit2 |
slit guidance ligand 2 |
increases expression |
ISO |
belinostat results in increased expression of SLIT2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
|
|
G |
Smarca2 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SMARCA2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:224,191,125...224,358,640
Ensembl chr 1:224,191,125...224,358,684
|
|
G |
Smoc1 |
SPARC related modular calcium binding 1 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of SMOC1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:100,701,330...100,897,441
Ensembl chr 6:100,701,346...100,862,699
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SNAI2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snap25 |
synaptosome associated protein 25 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SNAP25 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Snx10 |
sorting nexin 10 |
decreases expression |
ISO |
belinostat results in decreased expression of SNX10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
decreases expression |
ISO |
belinostat results in decreased expression of SOCS3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sox6 |
SRY-box transcription factor 6 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:169,723,306...170,334,846
Ensembl chr 1:169,729,194...170,277,386
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of SOX8 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818
|
|
G |
Spink2 |
serine peptidase inhibitor, Kazal type 2 |
increases expression |
ISO |
belinostat results in increased expression of SPINK2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr14:30,967,682...30,974,326
Ensembl chr14:30,967,714...30,974,326
|
|
G |
Spx |
spexin hormone |
decreases expression |
ISO |
belinostat results in decreased expression of SPX mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:175,356,044...175,362,082
Ensembl chr 4:175,356,247...175,362,082
|
|
G |
Sspn |
sarcospan |
decreases expression |
ISO |
belinostat results in decreased expression of SSPN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554
|
|
G |
Sst |
somatostatin |
increases expression |
ISO |
belinostat results in increased expression of SST mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
ISO |
belinostat results in decreased expression of STC2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Stk32a |
serine/threonine kinase 32A |
decreases expression |
ISO |
belinostat results in decreased expression of STK32A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:35,258,865...35,374,985
Ensembl chr18:35,259,052...35,369,451
|
|
G |
Stmn2 |
stathmin 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of STMN2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases expression multiple interactions decreases expression |
ISO |
belinostat results in increased expression of SULT1C2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA belinostat results in decreased expression of SULT1C2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression |
ISO |
belinostat results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Susd1 |
sushi domain containing 1 |
decreases expression |
ISO |
belinostat results in decreased expression of SUSD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:74,157,653...74,281,171
Ensembl chr 5:74,157,773...74,276,291
|
|
G |
Synj2 |
synaptojanin 2 |
decreases expression |
ISO |
belinostat results in decreased expression of SYNJ2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:46,518,594...46,621,919
Ensembl chr 1:46,518,709...46,633,687
|
|
G |
Synm |
synemin |
decreases expression |
ISO |
belinostat results in decreased expression of SYNM mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:121,333,712...121,363,652
Ensembl chr 1:121,333,720...121,363,652
|
|
G |
Tacc1 |
transforming, acidic coiled-coil containing protein 1 |
increases expression |
ISO |
belinostat results in increased expression of TACC1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr16:66,812,232...66,895,736
Ensembl chr16:66,812,295...66,895,733
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA belinostat results in increased expression of TACSTD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:96,707,950...96,709,650
Ensembl chr 4:96,707,951...96,709,650
|
|
G |
Tafa2 |
TAFA chemokine like family member 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TAFA2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:58,942,598...59,418,640
Ensembl chr 7:58,942,610...59,417,299
|
|
G |
Taok3 |
TAO kinase 3 |
increases expression |
ISO |
belinostat results in increased expression of TAOK3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr12:39,312,354...39,473,656
Ensembl chr12:39,314,027...39,461,244
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TC2N mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
|
|
G |
Tcaim |
T cell activation inhibitor, mitochondrial |
decreases expression |
ISO |
belinostat results in decreased expression of TCAIM mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:122,414,827...122,446,105
Ensembl chr 8:122,414,818...122,446,092
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TFAP2A mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tfap2b |
transcription factor AP-2 beta |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TFAP2B mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:21,786,258...21,814,520
|
|
G |
Tfap2c |
transcription factor AP-2 gamma |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TFAP2C mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:161,315,114...161,322,998
Ensembl chr 3:161,315,031...161,322,995
|
|
G |
Tff1 |
trefoil factor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of TFF1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tff2 |
trefoil factor 2 |
decreases expression |
ISO |
belinostat results in decreased expression of TFF2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TFPI mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
ISO |
belinostat results in increased expression of TGFB2 mRNA |
CTD |
PMID:23671600 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Thrb |
thyroid hormone receptor beta |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of THRB mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
decreases expression |
ISO |
belinostat results in decreased expression of TIMP3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tmem220 |
transmembrane protein 220 |
decreases expression |
ISO |
belinostat results in decreased expression of TMEM220 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:51,719,777...51,728,792
Ensembl chr10:51,719,777...51,728,776
|
|
G |
Tmem221 |
transmembrane protein 221 |
decreases expression |
ISO |
belinostat results in decreased expression of TMEM221 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:18,253,622...18,271,094
Ensembl chr16:18,262,052...18,266,967
|
|
G |
Tmem30b |
transmembrane protein 30B |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA belinostat results in increased expression of TMEM30B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:92,251,626...92,254,702
Ensembl chr 6:92,249,790...92,254,842
|
|
G |
Tmem44 |
transmembrane protein 44 |
decreases expression |
ISO |
belinostat results in decreased expression of TMEM44 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958
|
|
G |
Tmem51 |
transmembrane protein 51 |
decreases expression |
ISO |
belinostat results in decreased expression of TMEM51 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:154,325,853...154,375,882
Ensembl chr 5:154,325,856...154,375,882
|
|
G |
Tmem64 |
transmembrane protein 64 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TMEM64 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:28,698,947...28,745,384
Ensembl chr 5:28,698,918...28,745,330
|
|
G |
Tnc |
tenascin C |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of TNC mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnik |
TRAF2 and NCK interacting kinase |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TNIK mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:111,184,387...111,580,750
|
|
G |
Tnn |
tenascin N |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:72,319,160...72,386,362
Ensembl chr13:72,319,155...72,408,156
|
|
G |
Tox2 |
TOX high mobility group box family member 2 |
decreases expression multiple interactions |
ISO |
belinostat results in decreased expression of TOX2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:151,853,294...151,980,086
Ensembl chr 3:151,853,294...151,980,749
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
belinostat results in decreased expression of TP53 mRNA belinostat results in decreased expression of TRP53 mRNA; belinostat results in decreased expression of TRP53 protein |
CTD |
PMID:19606018 PMID:29733868 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpd52l1 |
TPD52 like 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TPD52L1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
belinostat results in decreased expression of TPX2 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
belinostat results in decreased expression of TRIB3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trnp1 |
TMF1-regulated nuclear protein 1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TRNP1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:145,706,427...145,713,279
Ensembl chr 5:145,706,094...145,713,272
|
|
G |
Ttc29 |
tetratricopeptide repeat domain 29 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of TTC29 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:29,531,707...29,750,635
Ensembl chr19:29,532,663...29,750,615
|
|
G |
Tuba1a |
tubulin, alpha 1A |
affects expression |
ISO |
belinostat affects the expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tuft1 |
tuftelin 1 |
increases expression |
ISO |
belinostat results in increased expression of TUFT1 mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
increases expression |
ISO |
belinostat results in increased expression of TWIST1 protein |
CTD |
PMID:23671600 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Txnrd3 |
thioredoxin reductase 3 |
decreases expression |
ISO |
belinostat results in decreased expression of TXNRD3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:122,072,548...122,112,493
Ensembl chr 4:122,072,548...122,112,491
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression |
ISO |
belinostat results in decreased expression of TYMS mRNA |
CTD |
PMID:19606018 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases glucuronidation increases glucuronidation multiple interactions |
ISO |
UGT1A1 gene polymorphism results in decreased glucuronidation of belinostat UGT1A1 protein results in increased glucuronidation of belinostat belinostat inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone] |
CTD |
PMID:23382909 PMID:33290829 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
belinostat inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Hymecromone] |
CTD |
PMID:33290829 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
ISO |
belinostat inhibits the reaction [[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A6 protein results in increased glucuronidation of Hymecromone] |
CTD |
PMID:33290829 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
belinostat inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Hymecromone] |
CTD |
PMID:33290829 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Ugt3a1 |
UDP glycosyltransferase family 3 member A1 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of UGT3A1 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:58,327,058...58,350,186
Ensembl chr 2:58,334,603...58,350,186
|
|
G |
Ugt8 |
UDP glycosyltransferase 8 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of UGT8 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:214,264,483...214,332,660
|
|
G |
Unc93a |
unc-93 homolog A |
decreases expression |
ISO |
belinostat results in decreased expression of UNC93A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:52,973,143...53,029,578
Ensembl chr 1:52,980,724...53,029,663
|
|
G |
Ung |
uracil-DNA glycosylase |
decreases expression |
ISO |
belinostat results in decreased expression of UNG mRNA |
CTD |
PMID:29733868 |
|
NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206
|
|
G |
Usp28 |
ubiquitin specific peptidase 28 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of USP28 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:49,325,766...49,386,229
Ensembl chr 8:49,325,867...49,386,229
|
|
G |
Utf1 |
undifferentiated embryonic cell transcription factor 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA belinostat results in increased expression of UTF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:194,740,339...194,741,465
Ensembl chr 1:194,740,339...194,741,465
|
|
G |
Uts2b |
urotensin 2B |
decreases expression |
ISO |
belinostat results in decreased expression of UTS2B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:73,424,385...73,439,429
Ensembl chr11:73,424,385...73,439,429
|
|
G |
Vash2 |
vasohibin 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of VASH2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:102,529,718...102,561,204
Ensembl chr13:102,529,719...102,560,391
|
|
G |
Ventx |
VENT homeobox |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of VENTX mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:86,483,893...86,484,900
Ensembl chr X:86,483,893...86,484,954
|
|
G |
Veph1 |
ventricular zone expressed PH domain-containing 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:150,291,379...150,537,491
Ensembl chr 2:150,296,573...150,537,266
|
|
G |
Vim |
vimentin |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of VIM protein pyrvinium inhibits the reaction [belinostat results in increased expression of VIM protein] |
CTD |
PMID:23671600 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wfdc2 |
WAP four-disulfide core domain 2 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of WFDC2 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:153,286,946...153,314,832
Ensembl chr 3:153,286,131...153,292,807
|
|
G |
Wif1 |
Wnt inhibitory factor 1 |
decreases expression |
ISO |
belinostat results in decreased expression of WIF1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360
|
|
G |
Wnt3a |
Wnt family member 3A |
increases expression |
ISO |
belinostat results in increased expression of WNT3A mRNA |
CTD |
PMID:23671600 |
|
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Wnt4 |
Wnt family member 4 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of WNT4 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA |
CTD |
PMID:23671600 PMID:26272509 PMID:27188386 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt5b |
Wnt family member 5B |
decreases expression |
ISO |
belinostat results in decreased expression of WNT5B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:152,609,566...152,733,790
Ensembl chr 4:152,609,569...152,733,407
|
|
G |
Wnt7b |
Wnt family member 7B |
increases expression |
ISO |
belinostat results in increased expression of WNT7B mRNA |
CTD |
PMID:23671600 |
|
NCBI chr 7:116,634,817...116,679,459
Ensembl chr 7:116,634,814...116,679,581
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
multiple interactions |
ISO |
belinostat results in decreased degradation of and results in increased stability of and results in increased expression of WWTR1 protein; pyrvinium inhibits the reaction [belinostat results in increased expression of WWTR1 protein] |
CTD |
PMID:23671600 |
|
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
|
|
G |
Xkr6 |
XK related 6 |
increases expression |
ISO |
belinostat results in increased expression of XKR6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:37,857,096...38,059,699
Ensembl chr15:37,857,096...38,059,682
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases expression |
ISO |
belinostat results in decreased expression of XRCC1 mRNA; belinostat results in decreased expression of XRCC1 protein |
CTD |
PMID:29733868 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions |
ISO |
belinostat results in decreased expression of and results in decreased phosphorylation of YAP1 protein |
CTD |
PMID:23671600 |
|
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
|
|
G |
Zbtb1 |
zinc finger and BTB domain containing 1 |
decreases expression |
ISO |
belinostat results in decreased expression of ZBTB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:95,096,838...95,125,811
Ensembl chr 6:95,096,387...95,118,996
|
|
G |
Zbtb38 |
zinc finger and BTB domain containing 38 |
decreases expression |
ISO |
belinostat results in decreased expression of ZBTB38 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:97,284,617...97,288,518
Ensembl chr 8:97,280,993...97,485,625
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
G |
Zfp185 |
zinc finger protein 185 |
decreases expression |
ISO |
belinostat results in decreased expression of ZNF185 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:150,831,869...150,877,652
Ensembl chr X:150,831,862...150,874,810
|
|
G |
Zfp266 |
zinc finger protein 266 |
increases expression |
ISO |
belinostat results in increased expression of ZNF562 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:19,030,766...19,061,381
Ensembl chr 8:19,030,768...19,060,937
|
|
G |
Zfp36 |
zinc finger protein 36 |
decreases expression |
ISO |
belinostat results in decreased expression of ZFP36 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|
G |
Zfp397 |
zinc finger protein 397 |
increases expression |
ISO |
belinostat results in increased expression of ZNF397 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:15,241,764...15,253,148
Ensembl chr18:15,242,096...15,300,984
|
|
G |
Zfp42 |
zinc finger protein 42 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ZFP42 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:48,836,463...48,845,443
Ensembl chr16:48,836,648...48,845,401
|
|
G |
Zic3 |
Zic family member 3 |
increases expression multiple interactions |
ISO |
belinostat results in increased expression of ZIC3 mRNA [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:136,123,662...136,129,627
Ensembl chr X:136,124,026...136,134,746
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
belinostat results in increased expression of ZMAT3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863
|
|
G |
Zmym6 |
zinc finger MYM-type containing 6 |
decreases expression |
ISO |
belinostat results in decreased expression of ZMYM6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:139,396,374...139,444,357
Ensembl chr 5:139,396,727...139,444,279
|
|
G |
Znf750 |
zinc finger protein 750 |
increases expression |
ISO |
belinostat results in increased expression of ZNF750 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:106,772,162...106,781,186
Ensembl chr10:106,772,669...106,781,200
|
|